The insulin pricing lawsuit landscape shifted dramatically in 2026, as a federal appeals court dismissed the pharmacy benefit managers’ (PBMs’) countersuit against the Federal Trade Commission, regulatory settlements with two of the three major PBMs took shape, and a sprawling multi-district litigation continued to gather momentum in New Jersey. For the millions of Americans with diabetes who have watched insulin prices climb more than 1,000% over two decades, these converging legal and regulatory actions represent the most significant accountability push in the history of insulin pricing in the United States.
What Is the Insulin Pricing Lawsuit and Why It Matters in 2026
The insulin pricing lawsuit known formally as In re: Insulin Pricing Litigation, MDL 3080, is pending before Judge Brian R. Martinotti in the U.S. District Court for the District of New Jersey. As of September 2, 2026, the Judicial Panel on Multidistrict Litigation reported 435 active cases pending in the docket. The defendants named across these cases include insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi, alongside pharmacy benefit managers CVS Caremark, Express Scripts, and OptumRx — collectively accused of orchestrating a scheme to artificially inflate insulin list prices while extracting rebates that enriched the supply chain at the expense of patients paying out of pocket.
The core allegation is straightforward but staggering in scale: insulin list prices rose more than 1,000% over the past 20 years, not because of innovation or manufacturing costs, but because of a coordinated rebate system that rewarded PBMs for placing higher-priced insulins on formularies. The FTC has found that the three PBMs named in MDL 3080 hold oligopolistic control over approximately 80% of U.S. prescriptions, giving them extraordinary leverage over which drugs patients can access and at what cost.
FTC Regulatory Actions: Settlements, Consent Orders, and a Court Victory
Express Scripts Landmark Settlement — February 2026
On February 4, 2026, the Federal Trade Commission secured what it described as a landmark settlement with Express Scripts (operating under Cigna’s Evernorth subsidiary). Under the terms of the agreement, Express Scripts must stop preferring high-list-price drugs on its standard formularies and must delink its compensation from manufacturer savings negotiations — a structural change designed to eliminate the financial incentive that critics say drove insulin prices upward for years. The settlement also includes provisions requiring Express Scripts to work more cooperatively with local pharmacies and to relocate its Ascent Health Services operations from Switzerland to the United States, bringing greater transparency and domestic regulatory oversight to its drug pricing infrastructure. The FTC projects these changes could lower patient out-of-pocket insulin costs by up to $7 billion over 10 years. For diabetic patients whose insulin costs ballooned under Express Scripts-administered plans, this settlement is both a vindication and a potential source of future savings.
CVS Caremark Finalized Consent Order — July 2026
After months of regulatory review following the initial proposed consent order, the FTC announced the finalized settlement with CVS Caremark on July 14, 2026. The Caremark agreement follows the same structural logic as the Express Scripts settlement, targeting formulary design practices and competitive fairness in insulin pricing. Under the finalized order, Caremark is required to treat low-list-price insulin competitively on its formularies and must allow plan sponsors to move away from rebate guarantees and spread pricing — the very mechanisms that critics say created a perverse incentive to favor expensive insulins over affordable alternatives. The FTC estimates the Caremark settlement could generate projected patient savings of up to $8.5 billion over 10 years. Together, the Express Scripts and Caremark settlements represent a combined potential savings of more than $15 billion for American patients over the next decade — a figure that underscores just how deeply PBM pricing practices have affected diabetes care costs across the country.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.